New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease

Previous studies have shown that pramipexole might have the potential to improve depressive symptoms in patients with Parkinson's disease. To provide more evidence, in five Japanese patients at Hoehn & Yahr stage 1-3 we evaluated the Unified Parkinson's Disease Rating Scale (UPDRS), Ha...

Full description

Saved in:
Bibliographic Details
Published inHiroshima journal of medical sciences Vol. 60; no. 4; p. 79
Main Authors Harada, Toshihide, Ishizaki, Fumiko, Horie, Nobuko, Nitta, Yumiko, Yamada, Tohru, Sasaki, Tomohiro, Nagakane, Tomoomi, Yasumatsu, Yoshiteru, Nitta, Kohsaku, Katsuoka, Hiroyuki
Format Journal Article
LanguageEnglish
Published Japan 01.12.2011
Subjects
Aged
Aged, 80 and over
Benzothiazoles - pharmacology
Benzothiazoles - therapeutic use
Depression - complications
Depression - drug therapy
Dopamine Agonists - pharmacology
Dopamine Agonists - therapeutic use
Female
Humans
Male
Middle Aged
Parkinson Disease - complications
Parkinson Disease - drug therapy
Online AccessGet more information

Cover

More Information
Summary:Previous studies have shown that pramipexole might have the potential to improve depressive symptoms in patients with Parkinson's disease. To provide more evidence, in five Japanese patients at Hoehn & Yahr stage 1-3 we evaluated the Unified Parkinson's Disease Rating Scale (UPDRS), Hamilton Depression Rating Scale (HAMD) and Montgomery Asberg Depression Rating Scale (MADRS) at our hospital. After the pramipexole treatment, each total score of UPDRS, HAMD and MADRS significantly decreased compared with that before the treatment. Our data indicate that pramipexole improves depressive symptoms in patients with Parkinson's disease.
ISSN:0018-2052